| 4th Aug 2022 7:00 am |
RNS |
Lynparza approved in EU for early breast cancer |
| 1st Aug 2022 5:00 pm |
RNS |
Director/PDMR Shareholding |
| 1st Aug 2022 3:05 pm |
RNS |
Director/PDMR Shareholding |
| 1st Aug 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jul 2022 7:01 am |
RNS |
Chair succession |
| 29th Jul 2022 7:00 am |
RNS |
Half-year Report |
| 25th Jul 2022 7:10 am |
RNS |
Tezspire recommended for EU approval in asthma |
| 25th Jul 2022 7:05 am |
RNS |
Ultomiris recommended for EU approval for gMG |
| 25th Jul 2022 7:00 am |
RNS |
Enhertu granted Priority Review for HER2-low mBC |
| 19th Jul 2022 7:00 am |
RNS |
Enhertu approved in EU for HER2-positive mBC |
| 5th Jul 2022 7:00 am |
RNS |
AstraZeneca to acquire TeneoTwo and T cell engager |
| 1st Jul 2022 3:00 pm |
RNS |
Total Voting Rights |
| 30th Jun 2022 7:00 am |
RNS |
Imfinzi improved pCR in resectable lung cancer |
| 27th Jun 2022 7:05 am |
RNS |
Enhertu recommended for breast cancer EU approval |
| 27th Jun 2022 7:00 am |
RNS |
Lynparza recommended in EU for early breast cancer |
| 21st Jun 2022 7:00 am |
RNS |
Eplontersen Ph III trial met co-primary endpoints |
| 6th Jun 2022 7:00 am |
RNS |
Enhertu efficacy results in HER2-low breast cancer |
| 1st Jun 2022 3:00 pm |
RNS |
Block listing Interim Review |
| 1st Jun 2022 3:00 pm |
RNS |
Total Voting Rights |
| 20th May 2022 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 9th May 2022 1:00 pm |
RNS |
Appointment of joint corporate brokers |
| 6th May 2022 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 5th May 2022 7:10 am |
RNS |
Enhertu approved in US for 2L HER2+ breast cancer |
| 5th May 2022 7:05 am |
RNS |
Farxiga HFpEF Phase III trial met primary endpoint |
| 5th May 2022 7:00 am |
RNS |
Ultomiris NMOSD Ph. III trial met primary endpoint |
| 4th May 2022 7:00 am |
RNS |
Imfinzi combo granted Priority Review for BTC |
| 3rd May 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Apr 2022 5:30 pm |
RNS |
Result of AGM |
| 29th Apr 2022 7:05 am |
RNS |
AstraZeneca plans new R&D centre in Massachusetts |
| 29th Apr 2022 7:00 am |
RNS |
First quarter 2022 results |
| 28th Apr 2022 7:00 am |
RNS |
Ultomiris approved in the US for adults with gMG |
| 27th Apr 2022 7:00 am |
RNS |
Enhertu granted BTD for HER2-low breast cancer |
| 25th Apr 2022 7:00 am |
RNS |
Tremelimumab US Priority Review for Imfinzi combo |
| 19th Apr 2022 7:00 am |
RNS |
Enhertu granted Priority Review for HER2m NSCLC |
| 1st Apr 2022 3:00 pm |
RNS |
Total Voting Rights |
| 29th Mar 2022 7:00 am |
RNS |
Ondexxya approved in Japan for FXai reversal |
| 28th Mar 2022 7:00 am |
RNS |
Evusheld approved in the EU for COVID-19 |
| 25th Mar 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 24th Mar 2022 6:00 pm |
RNS |
Evusheld Positive EU CHMP Opinion |
| 24th Mar 2022 7:00 am |
RNS |
Update on CALLA Phase III trial for Imfinzi |
